



# RECOGNIZING THE VALUE



## OF TREATMENTS FOR IgG4-RD

**IgG4-RD IS A DEVASTATING, RARE DISEASE** with no FDA-approved treatments yet.



As new treatments become available, they can only help patients **IF THEY ARE ACCESSIBLE.**

Discussions of treatment value can **IMPACT PATIENT ACCESS.**

These conversations must include:



How patients value the treatment



Disease burden



Caregivers' experiences



Treatment side effects

But all too often, the organizations who determine **THE VALUE OF TREATMENTS** don't take these factors into account.

They may:




Exclude the patient or provider perspective



Use discriminatory metrics



Apply broad, population-based information



As new treatments are developed, organizations must use a **PATIENT-CENTERED MODEL OF VALUE.**

